Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Concert Pharmaceuticals Inc    CNCE

CONCERT PHARMACEUTICALS INC (CNCE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2018 08/13/2018 08/14/2018 08/15/2018 08/16/2018 Date
16.41(c) 16.39(c) 16.75(c) 16.34(c) 16.14(c) Last
55 096 136 936 151 226 116 419 76 586 Volume
-1.14% -0.12% +2.20% -2.45% -1.22% Change
More quotes
Financials (USD)
Sales 2018 10,5 M
EBIT 2018 -51,1 M
Net income 2018 -50,6 M
Finance 2018 21,3 M
Yield 2018 -
Sales 2019 10,4 M
EBIT 2019 -65,4 M
Net income 2019 -65,3 M
Finance 2019 20,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 34,5x
EV / Sales2019 34,8x
Capitalization 384 M
More Financials
Company
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology.Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system... 
More about the company
Surperformance© ratings of Concert Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on CONCERT PHARMACEUTICALS IN
08/16CONCERT PHARMACEUTICALS : Patent Issued for Substituted Triazolobenzodiazepines ..
AQ
08/08CONCERT PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Prov..
AQ
08/02CONCERT : 2Q Earnings Snapshot
AQ
08/02CONCERT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
08/02CONCERT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
AQ
08/02CONCERT PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Prov..
BU
07/30CONCERT PHARMACEUTICALS : to Report Second Quarter 2018 Financial Results on Aug..
AQ
07/26CONCERT PHARMACEUTICALS : to Report Second Quarter 2018 Financial Results on Aug..
BU
06/18CONCERT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
AQ
05/30CONCERT PHARMACEUTICALS : Northeast digital integrators selected as av systems i..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/14Want automatic email alerts for $TPH $GNCA $CNCE $FLXN $HSON? Subscribe to Ma.. 
08/10Recent Research Analysts’ Ratings Changes for Concert Pharmaceuticals $CNCE  
08/09Concert Pharmaceuticals $CNCE Given “Buy” Rating at HC Wainwright  
08/08Concert Pharmaceuticals’ $CNCE “Buy” Rating Reaffirmed at HC Wainwright  
08/08Consolidated Research: 2018 Summary Expectations for Independent Bank Group, .. 
More tweets
Qtime:88
News from SeekingAlpha
08/04Concert Pharmaceuticals Inc.'s (CNCE) CEO Roger Tung on Q2 2018 Results - Ear.. 
08/02Concert Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides 
08/02Concert Pharma beats by $0.05 
07/30FDA OKs Indivior's long-acting Perseris for schizophrenia 
06/19INSTITUTIONAL TOP IDEAS : Great Point Partners 
Chart CONCERT PHARMACEUTICALS INC
Duration : Period :
Concert Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CONCERT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 28,0 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Roger D. Tung President, Chief Executive Officer & Director
Richard H. Aldrich Chairman
Nancy Stuart Chief Operating Officer
Marc Becker Chief Financial Officer
Wilfred E. Jaeger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CONCERT PHARMACEUTICALS INC-37.61%384
CELLTRION, INC.--.--%29 145
IQVIA HOLDINGS INC22.78%24 472
LONZA GROUP18.34%23 390
INCYTE CORPORATION-29.40%14 126
SEATTLE GENETICS, INC.38.13%11 851